Cargando…

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial

OBJECTIVES: Elevated serum urate (SU) levels are associated with arterial atherosclerosis and subsequent cardiovascular events. However, an optimal therapeutic target SU level for delaying atherosclerotic progression in patients with hyperuricaemia remains uncertain. The aim of this analysis was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Toyoda, Shigeru, Kato, Toru, Yoshida, Hisako, Hamasaki, Shuichi, Watarai, Masato, Ishizu, Tomoko, Ueda, Shinichiro, Inoue, Teruo, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003608/
https://www.ncbi.nlm.nih.gov/pubmed/35410947
http://dx.doi.org/10.1136/rmdopen-2022-002226
_version_ 1784686167339302912
author Tanaka, Atsushi
Toyoda, Shigeru
Kato, Toru
Yoshida, Hisako
Hamasaki, Shuichi
Watarai, Masato
Ishizu, Tomoko
Ueda, Shinichiro
Inoue, Teruo
Node, Koichi
author_facet Tanaka, Atsushi
Toyoda, Shigeru
Kato, Toru
Yoshida, Hisako
Hamasaki, Shuichi
Watarai, Masato
Ishizu, Tomoko
Ueda, Shinichiro
Inoue, Teruo
Node, Koichi
author_sort Tanaka, Atsushi
collection PubMed
description OBJECTIVES: Elevated serum urate (SU) levels are associated with arterial atherosclerosis and subsequent cardiovascular events. However, an optimal therapeutic target SU level for delaying atherosclerotic progression in patients with hyperuricaemia remains uncertain. The aim of this analysis was to assess an association between changes in SU level and carotid intima–media thickness (IMT) to examine whether an optimal SU concentration exists to delay atherosclerotic progression. METHODS: This was a post hoc analysis of the PRIZE (programme of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicentre, randomised controlled) study of Japanese adults with asymptomatic hyperuricaemia. The primary endpoint of this analysis was an association between changes in SU levels and mean common carotid artery IMT (CCA-IMT) after 24 months of febuxostat treatment. RESULTS: Among subjects treated with febuxostat (n=239), a total of 204 who had both data on SU and mean CCA-IMT at baseline and 24 months were included in this analysis. The mean baseline SU level was 7.7±1.0 mg/dL, and febuxostat treatment significantly reduced SU concentrations at 24 months (estimated mean change ‒3.051 mg/dL, 95% CI ‒3.221 to ‒2.882). A multivariable linear regression analysis revealed that a reduction in SU level was associated with changes in mean CCA-IMT values at 24 months (p=0.025). In contrast, the achieved SU concentrations were not associated with changes in mean CCA-IMT at 24 months. CONCLUSION: A greater reduction in SU, but not its achieved concentrations, may be associated with delayed progression of carotid IMT in patients with asymptomatic hyperuricaemia treated with febuxostat. TRIAL REGISTRATION NUMBER: UMIN000012911
format Online
Article
Text
id pubmed-9003608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90036082022-04-27 Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial Tanaka, Atsushi Toyoda, Shigeru Kato, Toru Yoshida, Hisako Hamasaki, Shuichi Watarai, Masato Ishizu, Tomoko Ueda, Shinichiro Inoue, Teruo Node, Koichi RMD Open Crystal Arthropathies OBJECTIVES: Elevated serum urate (SU) levels are associated with arterial atherosclerosis and subsequent cardiovascular events. However, an optimal therapeutic target SU level for delaying atherosclerotic progression in patients with hyperuricaemia remains uncertain. The aim of this analysis was to assess an association between changes in SU level and carotid intima–media thickness (IMT) to examine whether an optimal SU concentration exists to delay atherosclerotic progression. METHODS: This was a post hoc analysis of the PRIZE (programme of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicentre, randomised controlled) study of Japanese adults with asymptomatic hyperuricaemia. The primary endpoint of this analysis was an association between changes in SU levels and mean common carotid artery IMT (CCA-IMT) after 24 months of febuxostat treatment. RESULTS: Among subjects treated with febuxostat (n=239), a total of 204 who had both data on SU and mean CCA-IMT at baseline and 24 months were included in this analysis. The mean baseline SU level was 7.7±1.0 mg/dL, and febuxostat treatment significantly reduced SU concentrations at 24 months (estimated mean change ‒3.051 mg/dL, 95% CI ‒3.221 to ‒2.882). A multivariable linear regression analysis revealed that a reduction in SU level was associated with changes in mean CCA-IMT values at 24 months (p=0.025). In contrast, the achieved SU concentrations were not associated with changes in mean CCA-IMT at 24 months. CONCLUSION: A greater reduction in SU, but not its achieved concentrations, may be associated with delayed progression of carotid IMT in patients with asymptomatic hyperuricaemia treated with febuxostat. TRIAL REGISTRATION NUMBER: UMIN000012911 BMJ Publishing Group 2022-04-10 /pmc/articles/PMC9003608/ /pubmed/35410947 http://dx.doi.org/10.1136/rmdopen-2022-002226 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Crystal Arthropathies
Tanaka, Atsushi
Toyoda, Shigeru
Kato, Toru
Yoshida, Hisako
Hamasaki, Shuichi
Watarai, Masato
Ishizu, Tomoko
Ueda, Shinichiro
Inoue, Teruo
Node, Koichi
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title_full Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title_fullStr Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title_full_unstemmed Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title_short Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
title_sort association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the prize randomised clinical trial
topic Crystal Arthropathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003608/
https://www.ncbi.nlm.nih.gov/pubmed/35410947
http://dx.doi.org/10.1136/rmdopen-2022-002226
work_keys_str_mv AT tanakaatsushi associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT toyodashigeru associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT katotoru associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT yoshidahisako associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT hamasakishuichi associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT wataraimasato associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT ishizutomoko associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT uedashinichiro associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT inoueteruo associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT nodekoichi associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial
AT associationbetweenserumuratelevelandcarotidatherosclerosisaninsightfromaposthocanalysisoftheprizerandomisedclinicaltrial